Contact Information
Research Team
Name Position Office Phone Email
Xin PEIPhD StudentN22-3013+853 8822 2953yc37653@um.edu.mo
Xue ZHANGResearch AssistantN22-3013+853 8822 2953xuezhang@um.edu.mo
Xin PEIPhD Student
PhD University of Chicago, USA, 2015
Nanjing Medical University, China, 2015
MSc Nanjing Medical University, China, 2012
BSc Southeast University, China, 2009
12/2022 – Present Assistant Professor, Faculty of Health Sciences, University of Macau, Macau SAR, China
10/2019 – 10/2022 Associate Professor & Attending Surgeon, Liver Cancer Program, Sun Yat-sen University Cancer Center, Guangzhou, China
03/2018 – 03/2019 Research Officer (Level 3), Cancer Immunotherapy Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia
08/2015 – 08/2019 Resident & Postdoctoral Fellow, Department of Liver Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Research Interests
In the light of liver-specific or therapy-induced cues within the cancer microenvironment, our group focuses on the mechanistic study of adaptive cell signaling and consequent immunomodulation, which may impact clinical outcome and illuminate combination immunotherapy. Typically, we are looking at how therapy-induced inflammation adapts T cell signaling, to explore whether the underlying molecular traits can apply to tailoring T cell-based immunotherapy.
Representative Publications
  1. Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation – have anti-inflammatory therapies come of age? Nature Reviews Clinical Oncology. 2021 May;18(5):261-279. doi: 10.1038/s41571-020-00459-9
  2. Hou J, Zhang H, Sun B, Karin M. The immunobiology of hepatocellular carcinoma in humans and mice: basic concepts and therapeutic implications. Journal of Hepatology. 2020 Jan;72(1):167-182. doi: 10.1016/j.jhep.2019.08.014.
  3. Wang J, Hu B, Zhang He, Zhao Zhenjun, Zhao Zhicong, Zhang Haiyan, Ma X, Shen B, Sun B, Huang X, Hou J (co-corresponding), Xia Q. Intracellular XBP1-IL-24 axis dismantles CHOP-mediated cytotoxic unfolded protein response in the liver. Cell Death & Disease. 2020 Jan;11(1):17. doi: 10.1038/s41419-019-2209-6.
  4. Hou J (co-corresponding), Zhang He, Liu J, Zhao Zhenjun, Wang J, Lu Z, Hu B, Zhou J, Zhao Zhicong, Feng M, Zhang Haiyan, Shen B, Huang X, Sun B, He C, Xia Q. YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Molecular Cancer 2019 Nov;18(1):163. doi: 10.1186/s12943-019-1082-3.
  5. Hou J, Greten T, Xia Q. Immunosuppressive cell death in cancer. Nature Reviews Immunology. 2017 Jun;17(6):401. doi: 10.1038/nri.2017.46.
  6. Hou J, Deng L, Zhuo H, Lin Z, Chen Y, Jiang R, Chen D, Zhang X, Huang X, Sun B. PTPROt maintains tumor immunity in the microenvironment of hepatocellular carcinoma. Journal of Molecular Cell Biology. 2015 Aug;7(4):338-50. doi: 10.1093/jmcb/mjv047.
  7. Hou J, Xia Y, Jiang R, Cheng D, Xu J, Deng L, Huang X, Wang X, Sun B. PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-κB. Journal of Hepatology. 2014 Feb;60(2):306-12. doi: 10.1016/j.jhep.2013.09.028.
  8. Chen C, Hou J (co-first author), Lin Z, Yao M, Jiang R, Wang Y, Gao Y, Shao Q, Deng L, Chen Y, Sun B. A bystander cell-based GM-CSF secreting vaccine synergizes with a low dose of cyclophosphamide and induces therapeutic immune responses against murine hepatocellular carcinoma. Cellular & Molecular Immunology. 2013 Jun;10(4):349-59. doi: 10.1038/cmi.2013.20.
  9. Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, Huang X, Wang X, Sun B. Estrogen sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 2013 Feb;57(2):678-88. doi: 10.1002/hep.25980.
Full publications list
Research Grants
2023 Type II Grant of Ministry of Education Frontiers Science Centre for Precision Oncology, University of Macau (SP2023-00001-FSCPO), MOP 200,000
2022 Start-up Fund, University of Macau, MOP 1,800,000
2022 General Program, National Natural Science Foundation of China (82271881), CNY 520,000
2020 Guangdong Provincial Science Fund for Distinguished Young Scholars (2021B1515020007), CNY 1,000,000
2019 Hundred Talent Program, Sun Yat-sen University (2019079), CNY 900,000
2018 General Program, National Natural Science Foundation of China (81871970), CNY 540,000
2016 Joint Program for Medicine and Engineering, Shanghai Jiaotong University, CNY 120,000
2016 General Program, National Natural Science Foundation of China (81672801), CNY 630,000
2015 Dawn Program, Shanghai Municipal Education Commission (15CG13), CNY 60,000
2013 Youth Program, National Natural Science Foundation of China (81302106), CNY230,000
Professional Activities
  • Membership of the American Association for Cancer Research
  • Membership of the Australasian Society for Immunology
  1. Hou J, Zhang H. A new use of Sodium-glucose Cotransporter-2 (SGLT2) inhibitor as a reagent for enhanced cancer immunotherapy. National Invention Patent of China (202211707300)
  2. Hou J, Yang Y, Chen Y, Sun B. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. National Invention Patent of China (201310598574)
  3. Sun B, Chen C, Hou J, Wang X. A nanoparticle-based GM-CSF slow-releasing vaccine against murine hepatocellular carcinoma. National Invention Patent of China (201210236543)
2020 Distinguished Young Scholars in Guangdong Province
2019 Hundred Talent Program in Sun Yat-sen University
2016 Excellent Resident in Renji Hospital
2015 Excellent Doctoral Thesis in Jiangsu Province
2015 Excellent Graduate of Nanjing Medical University
2014 Participant of the 64th Lindau Nobel Laureate Meetings (Germany)
2014 The University of Chicago Scholarship for Joint PhD Program (USA)
2014 National Scholarship for Excellent Postgraduates (China)
2013 National Scholarship for Excellent Postgraduates (China)
2012 Excellent Master Thesis in Jiangsu Province